Item 8.01 Other Events.

On December 8, 2020, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the results from the Company's open-label, Phase 2, COMET-SI trial of AXS-05 in patients with major depressive disorder who have suicidal ideation.

The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.                                 Description

99.1             Press Release dated December 8, 2020.
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document).










                                       1

© Edgar Online, source Glimpses